Skip to main content
Livermore
Livermore
ZHEN

Ultragenyx Pharmaceutical Inc.

RARE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001515673

In the last 90 days, Ultragenyx Pharmaceutical Inc. insiders filed 0 open-market purchases and 5 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $3.55B in total; no superinvestor holds it.

Holders of 5% or more of RARE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ultragenyx Pharmaceutical Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of RARE
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A5.10%4.82M shares–Apr 24, 20251 filingApr 24, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Ultragenyx Pharmaceutical Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on RARE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 27, 20261:54 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Feb 5, 20261:40 PM ETFMR LLCand 1 other13G/A3.50%3.35M shares−4.80 ppfrom 8.30%Below 5%Dec 31, 2025SEC
Nov 5, 202511:49 AM ETFMR LLCand 1 other13G8.30%7.96M sharesNewSep 30, 2025SEC
Apr 24, 20259:12 AM ETBlackRock, Inc.13G/A5.10%4.82M shares–Mar 31, 2025SEC
Feb 12, 202511:42 AM ETSands Capital Management, LLCand 1 other13G/A4.70%4.30M shares–Below 5%Dec 31, 2024SEC
Feb 10, 202510:25 AM ETWellington Management Group LLPand 2 others13G/A2.70%2.46M shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Ultragenyx Pharmaceutical Inc. shares.

No Form 144 notices for Ultragenyx Pharmaceutical Inc. are on file.